Announcement related-TTianjin Tianyao Pharmaceuticals Co., Ltd.

Home Home

About us About us

Our business Our business

News and Information News and Information

Chinese

English

News and Information

News and Information

Announcement related

Tianjin Pharmaceutical Group has achieved another success in its overseas expansion, obtaining a registration certificate in Panama for its methylprednisolone sodium succinate for injection.

On November 18th, Tianjin Pharmaceutical Group Co., Ltd. announced that its subsidiary, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd., had obtained a registration certificate from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate, signifying that the drug can be manufactured and sold in the Panamanian market. In April of this year, the same product also obtained a registration certificate from the Ministry of Health of the Dominican R

2025-11-18
Compound potassium hydrogen phosphate injection passes consistency evaluation, expanding its domestic pharmaceutical market.

On November 4th, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd., received the "Approval Notice for Supplementary Application of Compound Potassium Hydrogen Phosphate Injection" issued by the National Medical Products Administration, approving the product's compliance with the consistency evaluation of generic drug quality and efficacy. It is understood that Compound Potassium Hydrogen Phosphate Inje

2025-11-04
Tianjin Pharmaceutical Group's drug and psychotropic product pipeline gains a new addition: Butorphanol Tartrate Injection, which has been approved.

Recently, Tianjin Pharmaceutical Group's subsidiary, Tianjin Pharmaceutical Peace, received a Drug Registration Certificate from the National Medical Products Administration for Butorphanol Tartrate Injection. The drug's main ingredient is butorphanol tartrate, classified as a Class II psychotropic drug under the "Regulations on the Administration of Narcotic Drugs and Psychotropic Substances" in China, with indications for the treatment of various cancer pains and postoperative pain. This appro

2025-11-03
Tianjin Pharmaceutical Group's seven products are expected to be selected in the eleventh batch of centralized procurement, strengthening the advantages of its formulation business.

On October 29th, Tianjin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Tianjin Pharmaceutical") announced that its subsidiaries, Tianjin Pharmaceutical Heping and Hubei Tianjin Pharmaceutical, participated in the 11th batch of national centralized drug procurement organized by the National Joint Procurement Office for Drugs. Seven products, namely Betamethasone Sodium Phosphate Injection, Bromhexine Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Dihydroxypropylthe

2025-10-29
Compound Amino Acid (15) Dipeptide (2) Injection Receives Registration Certificate, Strengthening the Layout in the Formulation Field

On September 9th, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace, received a Drug Registration Certificate for Compound Amino Acid (15) Dipeptide (2) Injection issued by the National Medical Products Administration. It is understood that the amino acids provided by Compound Amino Acid (15) Dipeptide (2) Injection are a component of parenteral nutrition therapy, suitable for patients who cannot receive oral or enteral nutrit

2025-09-09
The approval of difluprednisolone active pharmaceutical ingredient strengthens the advantages of integrated API and formulation production.

On August 29, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that it recently received the "Approval Notice for Marketing Application of Difluprednisolone Chemical Raw Material" issued by the National Medical Products Administration. Difluprednisolone is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. Currently, its main market form is eye drops, primarily used to treat inflammation and pain related to eye surgery. Meanwhile, t

2025-08-29
The first domestically produced generic difluprednisolone eye drops has obtained a drug registration certificate.

On August 27, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace, received a Drug Registration Certificate for difluprednisolone eye drops issued by the National Medical Products Administration. This drug is the first generic version available in China. It is primarily used to treat inflammation and pain associated with eye surgery and is the company's first steroidal hormone eye drops. This approval is significant in breaking

2025-08-27

12 3 >|go toPage

Company Profile

Development History

Active Pharmaceutical Ingredient

Finished Dosage Forms

Exhibition and Events

News and Information

Contact Us

Sales of Active Pharmaceutical Ingredients

API Sales

API Marketing Center - Overseas Sales Division - API Sales Dept.

Tel: +86-022-65277510

Email: tianfa@tjpc.com.cn

Jinyao Pharmaceuticals (Singapore) PTE. LTD.

Tel: +65 6514 0579

Dar Sheng Trade & Technic Development Co. Ltd.

Tel: +1 (973) 218-2536

Sales of Finished Dosage Forms

FDF Sales

API Marketing Center - Overseas Sales Division - FDF Sales Dept.

Tel: +86 13902093969

Email: lizhao@vip.tjpc.com.cn

Hubei Jinyao foreign Trade Department

Tel: 0710-3227740

● Follow us

Official Accounts

Scan and follow us

津ICP备2024020218号-1 互联网药品信息备案凭证备案号：2023010016

Technical Support: jinkuncms This site supports IPV6

Cancel

添加微信好友，详细了解产品

使用企业微信
“扫一扫”加入群聊

复制成功

添加微信好友，详细了解产品

我知道了